University of Tennessee Health Science Center

Respira Technologies, Inc. Announces Partnership With The Plough Center For Sterile Drug Delivery At The University Of Tennessee Health Science Center

Retrieved on: 
Tuesday, March 22, 2022
Poseidon, Daou Technology Inc., UTHSC, Private sector, VMN, University of Tennessee Health Science Center, Multimedia, Pain management, IND, Panel, View, CA, COPD, CEDR, FDA, University, Partnership, Pharmaceutical industry, Medical device, Asthma

Respira Technologies, Inc. is pursuing FDA authorization by CEDR as the first inhalable prescription smoking cessation therapy.

Key Points: 
  • Respira Technologies, Inc. is pursuing FDA authorization by CEDR as the first inhalable prescription smoking cessation therapy.
  • The Plough Center, a non-profit sterile drug delivery organization, provides best in class pharmaceutical drug product services to early-stage biotech and pharma companies advancing technologies that can have a significant impact on our society.
  • The RespiRxis a combination device where the sterile drug product is filled aseptically in a disposable cartridge which also includes the proprietary aerosol generating engine.
  • Maintaining sterility of the drug product and effectively complying with FDA's container closure requirements requires best in class capabilities.

GeneCentric to Present Discovery and Initial Clinical Utility of a Novel RNA-Based Gene Signature That Predicts Treatment Response in Patients With Head and Neck Cancer

Retrieved on: 
Thursday, March 17, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Association, Survival, Neoplasm, Therapy, Department, Tobacco, Technology, University, Â, Patient, AACR, Washington University School of Medicine, American Association, American Association for Cancer Research, Annual general meeting, MPH, University of Tennessee Health Science Center, Oncology, George Washington University School of Medicine & Health Sciences, Radiation, Head, Population, Exploration, Cancer, Death, Precision medicine, HNSCC, Biotechnology, HPV, LinkedIn, RNA, Pharmaceutical industry, Vaccine, MD, Head and Neck Cancer, GeneCentric, HEAD AND NECK CANCER, GENECENTRIC

Multiple independent retrospective datasets were utilized as part of the initial signature discovery, including those providing for its initial clinical utility.

Key Points: 
  • Multiple independent retrospective datasets were utilized as part of the initial signature discovery, including those providing for its initial clinical utility.
  • Oral cavity HNSCC patients with lymph node-negative disease, who are typically treated with surgical resection without additional radiation and/or chemotherapy, were identified as mesenchymal or non-mesenchymal based upon the novel RNA-based signature.
  • For the nearly one-quarter who were mesenchymal, survival was 2.4-fold worse compared to the remaining non-mesenchymal patients.
  • Further demonstration of clinical utility is ongoing, as well as initial test development discussions with several commercial reference laboratories.

New Data Demonstrate NovaGuide™ Intelligent Ultrasound Significantly Improves Detection of Right-to-Left Shunt

Retrieved on: 
Friday, February 11, 2022
University of Tennessee Health Science Center, Patient, Traumatic brain injury, PFO, Dementia, Risk, Stroke, Assistant, Recurrence, Brain, Travel, Standard of care, TTE, NVS, RLS, Robotics, FDA, Population, Â, Neurology, American Heart, Patent, Physician, Focal neurologic signs, Diagnosis, University, Conference, Intelligence, TCD, Cloud computing, GLOBE, Medical imaging, Pharmaceutical industry, MD

LOS ANGELES, Feb. 11, 2022 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, today announced the results of a multi-center, prospective, single-arm study which show the autonomous NovaGuide™ Intelligent Ultrasound is three times more likely to detect right-to-left shunt (RLS) – a recognized risk factor for stroke – than standard of care transthoracic echocardiography (TTE). The study results were presented in a late-breaking science session at the American Heart Association 2022 International Stroke Conference, held in New Orleans, LA and virtually from February 9–11, 2022.

Key Points: 
  • RLS is a known risk factor for stroke and these study findings underscore the importance of utilizing NovaGuide as a diagnostic technology.
  • It substantially improves detection of RLS compared to current standard of care.
  • The primary outcome was the percent shunt detection rate of NovaGuide relative to standard of care TTE.
  • The companys FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time.

Provectus Biopharmaceuticals Announces Publication of Pharmaceutical-Grade Rose Bengal’s Activity Against Gram-Positive Bacteria

Retrieved on: 
Monday, January 10, 2022
University of Tennessee Health Science Center, Safety, OTCQB, Skin, Bacteria, Legislation, Drug of last resort, NIH, Toxicity, Forward-looking statement, National, List of pharmacy schools, Research, Immunotherapy, Company, Doctor of Philosophy, MDR, University, Dye, Pharmacy, LED, GLOBE, Department, Pharmaceutical industry, Vaccine, Electric motor, Molecule

The article, entitled Antibacterial Activity of Pharmaceutical-Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies, may be accessed at: https://www.mdpi.com/1420-3049/27/1/322/htm .

Key Points: 
  • The article, entitled Antibacterial Activity of Pharmaceutical-Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies, may be accessed at: https://www.mdpi.com/1420-3049/27/1/322/htm .
  • These activity data and the favorable safety profile of Provectus pharmaceutical-grade rose bengal drug substance support the advancement of a drug formulation into the clinic as a broad-spectrum antibacterial agent.
  • Mr. Rodrigues added, Provectus pharmaceutical-grade rose bengal drug substance is produced by a proprietary 21st-century manufacturing process, using quality-by-design principles under good manufacturing practices at commercial scale, that consistently synthesizes the Companys rose bengal molecule.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes that includes rose bengal sodium.

GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer

Retrieved on: 
Tuesday, December 21, 2021
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Lung cancer, University, LabCorp, Therapy, RNA-Seq, Pembrolizumab, DNA, Technology, LinkedIn, Neoplasm, Exploration, University of Tennessee Health Science Center, Genomics, Biotechnology, Precision medicine, Lung, Population, NSCLC, RNA, Cancer, Patient, LUAD, Pharmaceutical industry, Medical imaging, the Piedmont Study, GeneCentric, THE PIEDMONT STUDY, GENECENTRIC

We founded GeneCentric over a decade ago to study the genomics of lung cancer using the deep insights that can be obtained through gene expression analysis, said Neil Hayes, M.D., GeneCentric co-founder and Director of the University of Tennessee Health Science Center for Cancer Research.

Key Points: 
  • We founded GeneCentric over a decade ago to study the genomics of lung cancer using the deep insights that can be obtained through gene expression analysis, said Neil Hayes, M.D., GeneCentric co-founder and Director of the University of Tennessee Health Science Center for Cancer Research.
  • While our work has expanded well beyond the lung, the actionable clinical and genomic datasets we have developed have led to multiple signatures and related prototype tests.
  • GeneCentric Therapeutics, Inc. is an RNA-based genomic solutions provider based in Durham, North Carolina.
  • GeneCentric commercializes its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout preclinical testing, clinical drug development and commercialization lifecycle phases.

myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients than Physician Prescribed Treatment

Retrieved on: 
Tuesday, December 14, 2021
Technology, Clinical Trials, Software, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Personalized medicine, TRI, Haematopoietic system, Clinical trial, CR, Metastasis, Abstract, Survival, Probability, DNA repair, CBM, University of Tennessee Health Science Center, Research, Genomics, Artificial intelligence, City, TCGA, MD, ASH, Chair, Society, Genome, Group, Leukemia, Cancer, Predictive genomics, Exposition, Agilent Technologies, DNA, Cytogenetics, Software, Drug combination, Sequoia Capital, Apoptosis, Publication, Failure, Leukemia Research, Lymphatic system, AML, Death, Immunology, Master of Science, Principal, PubMed, UnitedHealth Group, Patient, Department, University, Cell proliferation, Pharmaceutical industry, Medical imaging, Hematology

Through this personalized therapy biosimulation approach, we can individualize treatment selection and improve patient outcomes.

Key Points: 
  • Through this personalized therapy biosimulation approach, we can individualize treatment selection and improve patient outcomes.
  • The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.
  • However, comprehensive DNA sequencing used with Cellworks personalized therapy biosimulation can guide optimal treatment selection for individual patients, help patients avoid ineffective therapies and improve patient outcomes.
  • The Cellworks Biosimulation Platform was able to predict treatment benefit or failure better than physician prescribed treatment alone (likelihood ratio 12 = 14.86, p

Protecting the brain in sickle cell anemia: the value of beginning early in life

Retrieved on: 
Monday, December 6, 2021
Patient, Brain damage, Anti-transglutaminase antibodies, Experimental biology, Environment, Brain, Sickle cell disease, Infarction, Achievement Medal, Experimental Biology and Medicine, University, Washington University in St. Louis, Child, Hematology, University of Tennessee Health Science Center, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), USA, Society, Risk, Publishing, GLOBE, Thought, St. Jude Children's Research Hospital, Department, Life, Adolescence, Hydroxycarbamide, Vaccine, Pharmaceutical industry

Brain lesions among children living with sickle cell anemia is a prevalent problem with serious consequences later in life.

Key Points: 
  • Brain lesions among children living with sickle cell anemia is a prevalent problem with serious consequences later in life.
  • Lesions to the brain impair the brain's function, namely, the person's cognitive (or thinking) abilities, limiting their academic success and future earning potentials.
  • Dr. Hankins and colleagues performed one of the longest observational studies of children with sickle cell anemia.
  • Children were followed for up to 25 years, and their brains monitored for brain and vessel damage in young adulthood.

Pediatric neuroscientists from Le Bonheur Children's Hospital and the University of Tennessee Health Science Center to present at American Epilepsy Society Annual Meeting

Retrieved on: 
Thursday, December 2, 2021
U.S. News & World Report, Dentistry, Pediatrics, Pediatric Neurology, Review, Le Bonheur Children's Hospital, Achievement, MS, Diagnosis, AES, MBBS, News, Health, UTHSC, Student, University, Education, DNP, University of Tennessee Health Science Center, Research strategies of election campaign communication research, Mischer Neuroscience Institute, APRN, Transcranial magnetic stimulation, Twitter, Research, American Epilepsy Society, Instagram, Hospital, Le bonheur, Person, Maintenance, TMS, Epilepsy, Facebook, Walden University (Tennessee), Medicine, Pharmaceutical industry, Department store

The annual meeting is held each year for the epilepsy community to learn best practices and review breakthrough research.

Key Points: 
  • The annual meeting is held each year for the epilepsy community to learn best practices and review breakthrough research.
  • Le Bonheur serves as a primary teaching affiliate for the University Tennessee Health Science Center and trains more than 350 pediatricians and specialists each year.
  • Nationally recognized, Le Bonheur is ranked by U.S. News & World Report as a Best Children's Hospital.
  • The main campus in Memphis includes six colleges: Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing and Pharmacy.

Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting

Retrieved on: 
Tuesday, November 30, 2021
Senior, Sale, University, MD Anderson Cancer Center, Oncology, Christie, FOCUS, PHP, USF, University of Tennessee Health Science Center, Stanford University School of Medicine, Physician, The Christie NHS Foundation Trust, Center, Nasdaq, GLOBE, David Geffen School of Medicine at UCLA, Region, IIB, FDA, Department of Medicine – University of Pamplona, Melphalan, Principal investigator, Sarcoma, Interventional radiology, University of California, Division, Liver, Liver disease, Department, University College London, Pharmaceutical industry, Hospital

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd , from 10:00am ET 1:30pm EST.

Key Points: 
  • NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd , from 10:00am ET 1:30pm EST.
  • The event will focus on the companys US product candidate, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), a percutaneous hepatic perfusion (PHP) system.
  • In the United States HEPZATO is an investigational drug/device combination product.
  • The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

RedHill Biopharma Presents New Talicia® and Movantik® Data Analyses at ACG 2021

Retrieved on: 
Monday, October 25, 2021
Opioid, OIC, American College of Gastroenterology, TEL, Amoxicillin, ITT, Omeprazole, University, Helicobacter pylori, University of Tennessee Health Science Center, Guideline, Clarithromycin, History, CYP2C19, World Health Organization, FDA, World, FACG, PPI, Magnesium, Pivotal, Prescription, AGAF, Clinical trial, Chronic pain, Feinberg School of Medicine, WHO, American College, Nasdaq, Associate, Rifabutin, ACG, Physician, Pharmaceutical industry

TEL AVIV, Israel and RALEIGH, N.C., Oct. 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of four new analyses of Phase 3 Talicia (omeprazole magnesium, amoxicillin and rifabutin)[1] and Movantik (naloxegol)[2] data at the ACG 2021 Annual Scientific Meeting, taking place October 22-27, 2021.

Key Points: 
  • TEL AVIV, Israel and RALEIGH, N.C., Oct. 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of four new analyses of Phase 3 Talicia (omeprazole magnesium, amoxicillin and rifabutin)[1] and Movantik (naloxegol)[2] data at the ACG 2021 Annual Scientific Meeting, taking place October 22-27, 2021.
  • The first Talicia analysis evaluated physician-directed therapy data, confirming high utilization of clarithromycin and low rates of H. pylori eradication.
  • The two Movantik posters analyzed data from patients experiencing extreme opioid-induced constipation (OIC) with severe symptoms.
  • RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases.